Carol Ashe Net Worth

Carol Ashe biography

Carol Gail Ashe serves as Independent Director of the Company. She has been the Chief Business Officer at the New York Genome Center, an independent, nonprofit academic research institution focused on furthering genomic research that leads to scientific advances and new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer, since 2014. Previously, she served as Vice President of Corporate Development for Endo’s branded, generic and platform drug delivery pharmaceutical business units from 2011 to 2013; a Partner at SR One, the corporate venture capital fund of GlaxoSmithKline, from 2008 to 2010; and head of GSK’s US Corporate Legal Group supporting US-based mergers, acquisitions and equity investments from 2007 to 2008. Prior to that, Ms. Ashe led GSK’s global Business Development Transactions Legal Team supporting both the pharmaceutical and consumer healthcare business units from 1995 to 2007. Ms. Ashe received her BS degree in Biology from Pennsylvania State University, her law degree from Villanova University School of Law and is a registered patent attorney. Ms. Ashe makes valuable contributions to the Board based on over 25 years of experience in the pharmaceutical and biotechnology industry in business development and as legal counsel for business development transactions and patent matters.

What is the salary of Carol Ashe?

As the Independent Director of Aptose Biosciences Inc, the total compensation of Carol Ashe at Aptose Biosciences Inc is $107,630. There are 7 executives at Aptose Biosciences Inc getting paid more, with William Rice having the highest compensation of $1,511,900.

How old is Carol Ashe?

Carol Ashe is 62, she's been the Independent Director of Aptose Biosciences Inc since 2018. There are 4 older and 7 younger executives at Aptose Biosciences Inc. The oldest executive at Aptose Biosciences Inc is Denis Burger, 75, who is the Lead Independent Director.

What's Carol Ashe's mailing address?

Carol's mailing address filed with the SEC is 251 CONSUMERS ROAD, SUITE 1105, , TORONTO, A6, M2J 4R3.

Insiders trading at Aptose Biosciences Inc

Over the last 6 years, insiders at Aptose Biosciences Inc have traded over $2,827,381 worth of Aptose Biosciences Inc stock and bought 538,629 units worth $767,189 . The most active insiders traders include Erich Platzer, Bernd R. Seizinger e William G. Rice. On average, Aptose Biosciences Inc executives and independent directors trade stock every 59 days with the average trade being worth of $14,277. The most recent stock trade was executed by Bernd R. Seizinger on 22 September 2023, trading 17,000 units of APTO stock currently worth $53,380.

What does Aptose Biosciences Inc do?

aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt

Aptose Biosciences Inc executives and stock owners

Aptose Biosciences Inc executives and other stock owners filed with the SEC include:

• William Rice,
  Chairman of the Board, President, Chief Executive Officer
• Gregory Chow,
  Chief Financial Officer, Executive Vice President
• Jotin Marango,
  Senior Vice President, Chief Business Officer
• Dr. William G. Rice Ph.D.,
  Chairman, Pres & CEO
• Dr. Jotin Marango Ph.D., M.D.,
  Sr. VP, CFO, Chief Accounting Officer & Chief Bus. Officer
• Dr. Rafael Bejar M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Denis Burger,
  Lead Independent Director
• Caroline Loewy,
  Independent Director
• Carol Ashe,
  Independent Director
• Warren Whitehead,
  Independent Director
• Mark Vincent,
  Independent Director
• Erich Platzer,
  Independent Director
• Rafael Bejar,
  Senior Vice President, Chief Medical Officer
• Roger Davies B.Sc.,
  VP of Operations
• Bernd R. Seizinger,
  
• Fletcher Payne,
  Sr VP and CFO
• Philippe Ledru,